Ovarian Hyperstimulation Syndrome Clinical Trial
Official title:
Comparative Study Between Calcium Gluconate With Diosmin, Cabergoline and Cabergoline With Diosmin in Prevention of Ovarian Hyperstimulation Syndrome in High-risk Women Undergoing Intracytoplasmic Sperm Injection (ICSI) Procedures
Ovarian hyperstimulation syndrome is a potentially fatal iatrogenic condition. This syndrome is characterized by a sudden increase of the vascular permeability which results in the development of a massive extravascular exudate in the peritoneal cavity, pleural, pericardium causing ascites, pleural and pericardial effusion. Severe forms are also accompanied by electrolyte disturbances and cardiopulmonary, hepatic, renal, and hemoconcentration associated with increased thromboembolic risk. This syndrome is avoidable by the judicious use of gonadotropins and careful monitoring of stimulation regimens.
Ovarian hyperstimulation syndrome is a potentially fatal iatrogenic condition. The major step to prevent hyperstimulation syndrome is to determine high risk patients as presence of polycystic ovarian syndrome, younger women with greater ovarian responsiveness, use of super active GnRH agonists, development of multiple immature and intermediate follicle during treatment, exposure to LH/hCG and previous history of hyperstimulation syndrome. In addition, many different preventive modalities have been attempted such as decreasing the dose of FSH, using minimal or mild stimulating protocol as GnRH antagonists, use of insulin sensitizing agent as metformin, reduction the use of all follicles, decreasing the dose of hCG and administration of drugs which decrease capillary permeability as cabergoline, calcium gluconate, albumin, letrozole, hydroxyethyl starch and glucocorticoids. Several different drugs have been used for prevention of hyperstimulation syndromes. These include albumin, hydroxyethyl starch, aspirin, calcium, cabergoline, letrozole, and glucocorticoids. However, there is insufficient evidence about the benefits of these drugs in preventing hyperstimulation syndrome. Dopamine agonists (cabergoline) and calcium gluconate infusion are the most widely used preventive drugs. Although these drugs have comparable effectiveness in preventing hyperstimulation syndrome with fewer maternal side effects, calcium maybe associated with arrhythmia Recently attention has been focused on the use of Diosmin as a potent venotonic agent that decrease vascular permeability by reducing the release of inflammatory mediator such as prostaglandin E2 and thromboxane. A study found that the combined use of diosmin and cabergoline in high-risk women undergoing ART was competent in avoiding hyperstimulation syndrome than using cabergoline alone. Moreover, this combination does not affect pregnancy rate, miscarriage nor multiple pregnancy ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Withdrawn |
NCT00617864 -
The Effect of Human Albumin Infusion on VEGF Levels in Women at Risk for Ovarian Hyperstimulation Syndrome
|
N/A | |
Withdrawn |
NCT01979341 -
The Effect of a Dual Trigger on Intracytoplasmic Sperm Injection (ICSI) Reproductive Outcomes
|
N/A | |
Completed |
NCT01427335 -
Calcium for Prevention of Ovarian Hyperstimulation Syndrome
|
Phase 3 | |
Completed |
NCT01014104 -
Administration of Methylprednisolone for Prevention of Ovarian Hyper Stimulation Syndrome
|
Phase 1/Phase 2 | |
Recruiting |
NCT00119925 -
'SPRING'-Study: "Subfertility Guidelines: Patient Related Implementation in the Netherlands Among Gynaecologists"
|
N/A | |
Terminated |
NCT01714648 -
Can GnRH Agonist Trigger Prevent Ovarian Hyperstimulation Syndrome?
|
Phase 4 | |
Completed |
NCT01500863 -
Endometrial Receptivity After GnRH Agonist Triggering
|
Phase 4 | |
Recruiting |
NCT00417144 -
Comparison Between GnRH Agonist and GnRH Antagonist Protocols of Ovarian Stimulation in PCOS Patients
|
Phase 4 | |
Completed |
NCT03876145 -
The Four Methods of Ovarian Stimulation in Patients With Polycystic Ovarian Syndrome
|
N/A | |
Completed |
NCT05588635 -
Association Between Live Birth Rate and Serum Progesterone During Hormonal Replacement Therapy
|
||
Not yet recruiting |
NCT02392520 -
Luteal Antagonist Versus Conventional Treatment in Women With Severe Early Ovarian Hyperstimulation Syndrome (OHSS)
|
N/A | |
Completed |
NCT00665041 -
Tolerability of Quinagolide in a Dose-titration Regimen in Oocyte Donors at Risk of Developing Ovarian Hyperstimulation Syndrome
|
Phase 2 | |
Completed |
NCT00835523 -
Ovarian Hyperstimulation Syndrome (OHSS) Prevention With Agonist
|
N/A | |
Active, not recruiting |
NCT05638529 -
Dual Trigger" in IVF Patients at High Risk of Ovarian Hyper Stimulation Syndrome
|
Phase 4 | |
Not yet recruiting |
NCT03071172 -
Clinical Study of Recombinant Human Follitropin for Injection Assisted in COH Assisted IVF-ET
|
Phase 3 | |
Recruiting |
NCT02084940 -
Long Acting GnRH Antagonist in PCOS Women Undergoing IVF
|
N/A | |
Completed |
NCT01815138 -
Co-administration of Low Dose hCG at the Time of GnRH Agonist Trigger or 35 Hours Later for the Prevention of OHSS
|
Phase 4 | |
Completed |
NCT00867659 -
The Role of Cetrotide Acetate in Prevention of Ovarian Hyperstimulation Syndrome (OHSS) in Oocyte Donors
|
N/A | |
Completed |
NCT01569256 -
Ovarian Hyperstimulation Syndrome and Cabergoline
|
N/A | |
Not yet recruiting |
NCT05198128 -
Ovarian Hyperstimulation Syndrome Using Calcium Infusion
|
N/A |